Online inquiry

IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10264MR)

This product GTTS-WQ10264MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Choroiditis, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10264MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ386MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ11037MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ11045MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ11782MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ8033MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ11908MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ9969MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA KBSA301
GTTS-WQ11913MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MLN-1202
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW